Does Covid-19 or its vaccination make migraines worse?

Children and adolescents were twice as likely to experience long Covid after contracting Covid for the second time, compared to their peers with a single previous infection.

The Indian Council of Medical Research (ICMR), through its Regional Medical Research Centre, Bhubaneswar (RMRCBB) and National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology-National Institute of Immunology (DBT-NII), is currently developing a novel recombinant chimeric malaria vaccine candidate, named AdFalciVax.

The results show that childhood cancer survivors had a lower risk of contracting COVID 19, but were 58 per cent more likely to develop severe disease if they did become infected.

Using a newly devised, three-dimensional model to study the regeneration of nerve tissue in the nose, researchers at Tufts University School of Medicine and the Graduate School of Biomedical Sciences (GSBS) and colleagues have discovered that one type of stem cell thought to be dormant may play a more significant role in preserving the sense of smell than originally believed.

A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a study by researchers at the University of Pittsburgh School of Public Health and the Pennsylvania State University.

People with excess weight are more likely to experience long-term neurological and mental health symptoms after Covid-19, including headache, vertigo, smell and taste disorders, sleep disturbance, and depression.

Antidepressants, such as Prozac, are routinely used to treat mental health issues, but recent research reveals they may also protect against major infections and life-threatening sepsis. Scientists at the Salk Institute have now discovered how medications regulate the immune system and protect against infectious disease, providing insights that could lead to a new generation of life-saving treatments and improve global readiness for future pandemics.

A Covid-19 diagnosis is no longer as frightening as it used to be, thanks to developments in treatment choices. However, a new study reveals that leukocyte (white blood cell) count may now be used to identify who is more likely to develop more significant disease symptoms.

Researchers from the Universities of Arizona, Oxford, and Leeds examined dozens of previous studies on long Covid to investigate the number and range of people affected, the underlying disease mechanisms, the numerous symptoms that patients develop, and current and future treatments.

A new study shows that about two per cent of the population develop autoantibodies against type 1 interferons, mostly later in life. This makes individuals more susceptible to viral diseases like COVID-19. The study, conducted by University of Zurich (UZH) researchers together with a USZ team, is based on an analysis of a large collection of historical blood samples.